Pubmed Biomarker Relation Statistics Odds
(95% CI)		 P-value Description
34109467 HE4 high-risk group p<0.001 Serum HE4 levels was significantly associated with high-risk group
28751757 L1CAM low-risk histology classification p<0.001 Patients with high L1CAM expression in curettage specimen had significantly higher occurrence of lymph node metastases compared with patients with low expression of L1CAM in the subgroup with low-risk histology classification (30% vs 9% respectively
28618925 DJ-1 high-risk group 1073 vs 444 pg/mL 1073 vs 444 pg/mL p≤0.05 DJ-1 levels were significantly higher in high-risk EC versus low-risk EC
28618925 DJ-1 low-risk group 350 ± 76 vs 602 ± 86 pg/mL 350 ± 76 vs 602 ± 86 pg/mL p≤0.05 Among the low-risk group, DJ-1 serum levels were significantly higher in patients with MI ≥ 50% compared to patients with MI < 50%
27038842 CD103 high-risk adenocarcinoma patients p=0.031 The presence of a high CD103+ cell infiltration was associated with an improved prognosis in patients with endometrial adenocarcinoma .This beneficial effect was particularly evident in high-risk adenocarcinoma patients
26743472 L1CAM high-risk group p<0.001 L1CAM positivity was associated with high-risk endometrial cancer
26554657 CDK4/6 low-risk patient p=0.002 CDK4/6SA was significantly higher in pathologically low-risk patients (not receiving adjuvant chemotherapy, n=74) than in intermediate- or high-risk patients (receiving adjuvant chemotherapy, n=35).
26554657 CDK4/6 intermediate-/high-risk group/survival p=0.063 In the intermediate-/high-risk group, patients with high CDK4/6SA had a tendency of a more favourable prognosis compared with patients with low CDK4/6SA
26223178 HE4 high-risk patients 0.77 for HE vs 0.71 for CA125 0.77 for HE vs 0.71 for CA125 The cut-off 76.5 pmol/L is a better predictor in distinguishing the high-risk patients than CA125 better predictor in distinguishing the high-risk patients than CA125
26223178 HE4 discrimination p<0.001 In the case of HE4, there was a statistically significant difference between patients with low and high risk of the disease.
26045311 MTV myometrial invasion/high risk OR of 7.3 (CI, 2.9–18.3) p<0.001 adjusting for preoperative biopsy results suggesting high risk (nonendometrioid subtype or endometrioid grade 3), an MTV cutoff of 20 mL yielded an OR of 7.3 (CI, 2.9–18.3; P < 0.001) for deep invasion
34099314 glycine endometrial cancer risk OR1SD: 0.89, 95% CI: 0.80-0.99; Glycine was inversely associated with endometrial cancer risk
26045311 MTV high risk OR of 10.9 (CI, 2.1–55.3; p<0.005 adjusting for preoperative biopsy results suggesting high risk (nonendometrioid subtype or endometrioid grade 3),MTV cutoff of 30 mL yielded an OR of 10.9 (CI, 2.1–55.3; P < 0.005) for lymph node metastases.
25275055 Intraepithelial CD3(+) TIL counts risk groups HR=4.56, 95% CI=1.77-11.75 p=0.002 In multivariate analysis of patients with early tumors that included the TIL populations investigated and risk groups (high risk vs. low risk), intraepithelial CD3+ TIL counts below 17 per mm2 were associated with inferior prognosis
23266443 ERα/ERβ1 expression ratios risk HR, 6.4 [95% CI, 1.0-40.6; p=.04 An ERα/ERβ1 ratio of 1 or less has proved to be independently associated with a higher risk of death along with age, tumor stage, and Ki-67.
23266443 ERα/ERβ2 expression ratios risk HR,9.7 [95% CI, 1.1-85.3; p=.04 An ERα/ERβ2 ratio of 1 or less has proved to be independently associated with a higher risk of death respectively along with age, tumor stage, and Ki-67.
22889453 HSPA5 high-risk endometrial cancer p=0.007 The positive rate of HSPA5 was higher in high-risk EC tissue than in low-risk EC and normal endome-trial tissue (77.2% [44/57] versus 53.2% [33/62] and45.0% [9/20],
22644303 pHH3 risk stratification p<0.0001 The rate of pHH3-positive cells was significantly associated with risk stratification
21242118 Stathmin low-risk sensitivity = 0.44, specificity = 0.70, PPV = 0.13, and NPV = 0.92 sensitivity = 0.44, specificity = 0.70, PPV = 0.13, and NPV = 0.92 OR = 1.82 (95% CI: 0.93–3.57), Analyzing Stathmin expressions in curettage specimens in the low-risk curettage group separately, the multivariate OR is 1.82 (95% CI: 0.93–3.57), sensitivity = 0.44, specificity = 0.70, PPV = 0.13, and NPV = 0.92
8088605 CA 125 high-risk patients p=0.0026 Low-risk patients (G1 and M0-M1 tumors) showed a CA 125 positivity (> 35 U/ml) of 10% with respect to 37% of high-risk patients (G2-G3 and M2 tumors)
34802721 C-reactive protein p < 0.05 Women with pre-treatment CRP ≥5.5 mg/L had a 68% increase in overall (adjusted HR = 1.68, 95% CI 1.00-2.81, p = 0.049) and a two-fold higher cancer-specific mortality risk than those with CRP <5.5 mg/L (adjusted HR = 2.04, 95%CI 1.03-4.02, p = 0.04).
36251972 p53 risk P <0.001 Abnormal p53 IHC expression was expressed in 33.3% of the cases and significantly associated with the tumor grade, myometrial invasion (MI), lymphovascular invasion (LVSI), nodal metastasis, and FIGO stage, and the advanced European Society for Medical Oncology (ESMO) risk groups.
34099314 serine endometrial cancer risk OR1SD: 0.89, 95% CI: 0.79-1.00  Serine was inversely associated with endometrial cancer risk
36251972 Pirh2 high-risk group P =0.005 High IHC Pirh2 expression was noted in 58.3% of the cases, and significantly associated with high-risk group.
36251972 L1CAM high-risk group P =0.002 Positive L1CAM immunoexpression was noted in 26.7% and was significantly associated with high-risk group.
36690721 ER low-risk group Subgroup-analysis showed that only in NSMP HR-EC, ER-positivity was independently associated with a reduced risk of recurrence (HR 0.33, 95%CI 0.15-0.75).
34099314 SM C18:0 endometrial cancer risk OR1SD: 1.18, 95% CI: 1.05-1.33 Sphingomyelin [SM] C18:0 was inversely associated with endometrial cancer risk
34099314 free carnitine endometrial cancer risk OR1SD: 0.91, 95% CI: 0.81-1.00 Free carnitine (C0) was inversely associated with endometrial cancer risk
33237570 P53 risk [OR] 1.799, 95%CI 1.033–3.133, p=0.038 The high P53 index (>67%) was found to be an independent risk factor for the recurrence of endometrial cancer in multivariate Cox regression analysis, eliminating the effects of other factors
33197888 PPARγ(-)/ERRα(+) risk factor OR=14.847, 95% CI= 1.6-137.748 p=0.018 A PPARγ/ERRα ratio≤1.86 was an independent risk factor for endometrial carcinogenesis
29114696 cancer antigen 15-3 levels low-risk patient (16.2±7.1 [4.0-32.0] IU/mL vs 24.4±18.2 [4.0-153.0] IU/mL). (16.2±7.1 [4.0-32.0] IU/mL vs 24.4±18.2 [4.0-153.0] IU/mL). 95% confidence interval: 0.57−0.79 p=0.03 the mean serum CA15-3 levels were lower in low-risk patients compared to other patients with ECs
28751757 L1CAM low-risk group High expression of L1CAM in curettage specimen predicted poor disease-specific survival in within patients with low-risk curettage histology

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.